RecruitingEarly Phase 1NCT04645602
Merck IIT: RRP Pembro and Lenvatinib
Studying Recurrent respiratory papillomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yale University
- Principal Investigator
- Sara I Pai, MD, PHDYale University
- Intervention
- Lenvatinib(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Yale University, New Haven, Connecticut, United States
Collaborators
Eisai Inc. · Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04645602 on ClinicalTrials.govOther trials for Recurrent respiratory papillomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07317154Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) PatientsMayo Clinic
- RECRUITINGPHASE4NCT06538480Zopa Retreatment and Vector Shedding in Adults With RRPPrecigen, Inc
- RECRUITINGNANCT06412172The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)Massachusetts General Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05797246Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)National Cancer Institute (NCI)
- RECRUITINGNCT06000527Juvenile Recurrent Respiratory Papillomatosis: Establishment of a French National Cohort (PRR : National Cohort " REPA ")Imagine Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04724980Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisPrecigen, Inc
- ACTIVE NOT RECRUITINGPHASE2NCT02632344Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma PatientsMassachusetts General Hospital